The catechol O-methyltransferase Val158Met polymorphism is not associated with broad-based cognitive functioning in schizophrenia

Schizophrenia Research

Volumn 96, Issue 1-3, 2007, Pages 87-92

  Dickerson, Faith B ^a   Boronow, John J ^a   Stallings, Cassie ^a   Origoni, Andrea E ^a   Sullens, Anne ^a   Yolken, Robert H ^b  

^a SHEPPARD PRATT HEALTH SYSTEM   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cognition; COMT; Genetic; Schizophrenia

Indexed keywords

CATECHOL METHYLTRANSFERASE; METHIONINE; VALINE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; COGNITION; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PSYCHOLOGIC TEST; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; SCHIZOPHRENIA; SCORING SYSTEM; TASK PERFORMANCE; UNITED STATES; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIPSYCHOTIC AGENTS; CATECHOL O-METHYLTRANSFERASE; COGNITION; HUMANS; METHIONINE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VALINE;

EID: 34848880710     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.05.021     Document Type: Article

References (36)

1. Ayres A.M., Busatto G.F., Menezes P.R., Schaufelberger M.S., Coutinho L., Murray R.M., McGuire P.K., Rushe T., and Scazufca M. Cognitive deficits in first-episode psychosis: a population-based study in Sao Paulo, Brazil. Schizophr. Res. 90 1-3 (2007) 338-343
2. Bilder R.M., Volavka J., Czobor P., Malhotra A.K., Kennedy J.L., Ni X., Goldman R.S., Hoptman M.J., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J.P., Kunz M., Chakos M., Cooper T.B., and Lieberman J.A. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol. Psychiatry 52 7 (2002) 701-707 (Oct 1)
3. Burdick K.E., Lencz T., Funke B., Finn C.T., Szeszko P.R., Kane J.M., Kucherlapati R., and Malhotra A.K. Genetic variation in DTNBP1 influences general cognitive ability. Hum. Mol. Genet. 15 10 (2006) 1563-1568
4. Dickerson F.B., Boronow J.J., Stallings C., Origoni A.E., Ruslanova I., and Yolken R.H. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch. Gen. Psychiatry 60 5 (2003) 466-472
5. Dickerson F.B., Boronow J.J., Stallings C., Origoni A.E., Cole S., Leister F., Krivogorsky B., and Yolken R.H. The catechol O-methyltransferase Val158Met polymorphism and herpes simplex virus type 1 infection are risk factors for cognitive impairment in bipolar disorder: additive gene-environmental effects in a complex human psychiatric disorder. Bipolar Disord. 8 2 (2006) 124-132
6. Dickerson F., Boronow J., Stallings C., Origoni A., and Yolken R. The lymphotoxin Cys13Arg polymorphism and cognitive functioning in individuals with schizophrenia. Schizophr. Res. 89 1-3 (2007) 173-176
7. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzsanti C.M., Straub R.E., Goldman D., and Weinberger D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 98 12 (2001) 6917-6922
8. Egan M.F., Straub R.E., Goldberg T.E., Yakub I., Callicott J.H., Hariri A.R., Mattay V.S., Bertolino A., Hyde T.M., Shannon-Weickert C., Akil M., Crook J., Vakkalanka R.K., Balkissoon R., Gibbs R.A., Kleinman J.E., and Weinberger D.R. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 101 34 (2004) 12604-12609
9. Ehlis A.C., Reif A., Herrmann M.J., Lesch K.P., and Fallgatter A.J. Impact of catechol-O-methyltransferase on prefrontal brain functioning in schizophrenia spectrum disorders. Neuropsychopharmacology 32 1 (2007) 162-170
10. Goldberg T.E., Egan M.F., Gscheidle T., Coppola R., Weickert T., Kolachana B.S., Goldman D., and Weinberger D.R. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch. Gen. Psychiatry 60 9 (2003) 889-896
11. Goldberg T.E., Straub R.E., Callicott J.H., Hariri A., Mattay V.S., Bigelow L., Coppola R., Egan M.F., and Weinberger D.R. The G72/G30 gene complex and cognitive abnormalities in schizophrenia. Neuropsychopharmacology 31 9 (2006) 2022-2032
12. Golimbet V., Gritsenko I., Alfimova M., Lebedeva I., Lezheiko T., Abramova L., Kaleda V., and Ebstein R. Association study of COMT gene Val158Met polymorphism with auditory P300 and performance on neurocognitive tests in patients with schizophrenia and their relatives. World J. Biol. Psychiatry 7 4 (2006) 238-245
13. Harvey P.D. Cognitive and functional effects of atypical antipsychotic medications. J. Clin. Psychiatry 67 10 (2006) e13
14. Heinrichs R.W., and Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12 3 (1998) 426-445
15. Hennah W., Thomson P., Peltonen L., and Porteous D. Genes and schizophrenia: beyond schizophrenia: the role of DISC1 in major mental illness. Schizophr. Bull. 32 3 (2006) 409-416
16. Hilbe J. Sample size determination for means and proportions. Stata Tech. Bull. 11 (1993) 17-20
17. Ho B.C., Wassink T.H., O'Leary D.S., Sheffield V.C., and Andreasen N.C. Catechol-O-methyl transferase Val158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow. Mol. Psychiatry 10 3 (2005) 229,287-229,298
18. Ho B.C., Milev P., O'Leary D.S., Librant A., Andreasen N.C., and Wassink T.H. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch. Gen. Psychiatry 63 7 (2006) 731-740
19. Hobart M.P., Goldberg R., Bartko J.J., and Gold J.M. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia II. Convergent/discriminant validity and diagnostic groups comparisons. Am. J. Psychiatry 156 12 (1999) 1951-1957
20. Hori H., Noguchi H., Hashimoto R., Nakabayashi T., Omori M., Takahashi S., Tsukue R., Anami K., Hirabayashi N., Harada S., Saitoh O., Iwase M., Kajimoto O., Takeda M., Okabe S., and Kunugi H. Antipsychotic medication and cognitive function in schizophrenia. Schizophr. Res. 86 1-3 (2006) 138-146
21. Kay S.R. Positive and Negative Syndromes in Schizophrenia: Assessment and Research (1991), Bruner/Mazel, New York
22. Kerns J.G., and Berenbaum H. Cognitive impairments associated with formal thought disorder in people with schizophrenia. J. Abnorm. Psychology 111 2 (2002) 211-224
23. Leung A., and Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr. Scand., Suppl. 401 (2000) 3-38
24. Manning V., Wanigaratne S., Best D., Strathdee G., Schrover I., and Gossop M. Screening for cognitive functioning in psychiatric outpatients with schizophrenia, alcohol dependence, and dual diagnosis. Schizophr. Res. 91 1-3 (2007) 151-158 (Mar)
25. Mishara A.L., and Goldberg T.E. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol. Psychiatry 55 10 (2004) 1013-1022
26. Randolph C. RBANS Manual - Repeatable Battery for the Assessment of Neuropsychological Status (1998), Psychological Corporation, San Antonio, TX
27. Rosa A., Peralta V., Cuesta M.J., Zarzuela A., Serrano F., Martinez-Larrea A., and Fananas L. New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. Am. J. Psychiatry 161 6 (2004) 1110-1112
28. Rujescu D., Meisenzahl E.M., Krejcova S., Giegling I., Zetzsche T., Reiser M., Born C.M., Moller H.J., Veske A., Gal A., and Finckh U. Plexin B3 is genetically associated with verbal performance and white matter volume in human brain. Mol. Psychiatry 12 2 (2007) 190-194
29. Szekeres G., Keri S., Juhasz A., Rimanoczy A., Szendi I., Czimmer C., and Janka Z. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 24 1 (2004) 1-5
30. Szoke A., Schurhoff F., Meary A., Mathieu F., Chevalier F., Trandafir A., Alter C., Roy I., Bellivier F., and Leboyer M. Lack of influence of COMT and NET genes variants on executive functions in schizophrenic and bipolar patients, their first-degree relatives and controls. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141 5 (2006) 504-512
31. van Winkel R., Myin-Germeys I., Delespaul P., Peuskens J., De Hert M., and van Os J. Premorbid IQ as a predictor for the course of IQ in first onset patients with schizophrenia: a 10-year follow-up study. Schizophr. Res. 88 1-3 (2006) 47-54
32. Wassink T.H., Nopoulos P., Pietila J., Crowe R.R., and Andreasen N.C. NOTCH4 and the frontal lobe in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 118 1 (2003) 1-7
33. White T., Ho B.C., Ward .J., O'Leary D., and Andreasen N.C. Neuropsychological performance in first-episode adolescents with schizophrenia: a comparison with first-episode adults and adolescent control subjects. Biol. Psychiatry 60 5 (2006) 463-471
34. Wilk C.M., Gold J.M., Bartko J.J., Dickerson F., Fenton W.S., Knable M., Randolph C., and Buchanan R.W. Test-retest stability of the repeatable battery for the assessment of neuropsychological status in schizophrenia. Am. J. Psychiatry 159 5 (2002) 838-844
35. Woodward N.D., Jayathilake K., and Meltzer H.Y. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr. Res. 90 1-3 (2007) 86-96
36. Yue W., Kang G., Zhang Y., Qu M., Tang F., Han Y., Ruan Y., Lu T., Zhang J., and Zhang D. Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects. Neurosci. Lett. 416 1 (2007) 96-100 (Apr 6)